证券代码：000952 证券简称：广济药业 公告编号：2026-024 湖北广济药业股份有限公司 关于全资子公司收购控股孙公司少数股东股权 暨工商变更完成的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误 导性陈述或重大遗漏。 一、交易概述 1.湖北广济药业股份有限公司（以下简称"广济药业""公司"）全资子公 司湖北广济药业济康医药有限公司（以下简称"济康公司"）与武汉同科管理咨 询合伙企业（有限合伙）（以下简称"同科管理"）共同出资成立合资公司"湖 北长江广济医疗科技有限公司"（以下简称"长江广济公司"）。长江广济公司 注册资本 1000 万元，其中济康公司出资 510 万元，占长江广济公司 51%股权； 同科管理出资 490 万元，占长江广济公司 49%股权。 具体内容详见公司 2022 年 11 月 11 日刊登于《证券时报》《证券日报》《中 国证券报》和巨潮资讯网（www.cninfo.com.cn）上的《关于全资子公司投资设 立合资公司的公告》（公告编号：2022-085）。 2.基于公司当前经营发展情况，济康公司通过协议方式收购长江广济公司 49%股权。 本次交易的 ...

定增预案显示，此次发行的定价基准日为第十一届董事会第十五次（临时）会议决议公告日（2026年2 月12日），发行价格为6.32元/股，不低于定价基准日前20个交易日公司股票交易均价的80%，发行对象 只有一个，即控股股东长江产业集团。 从募资用途来看，6亿元资金将直接用于偿还借款和补充流动资金。广济药业在预案中坦言，此举旨在 优化资本结构，提高抗风险能力。 近期，广济药业（000952.SZ）的一纸公告，将这家老牌维生素生产商推至聚光灯下。 公司发布的《2026年度向特定对象发行A股股票预案》显示，拟向控股股东长江产业投资集团有限公司 （以下简称"长江产业集团"）定向发行不超过9493.67万股，募集资金总额不超过6亿元，扣除发行费用 后将全部用于偿还借款和补充流动资金。 在这场看似常规的再融资操作背后，是广济药业难以掩盖的经营窘境：连续三年巨额亏损、资产负债率 攀升至历史高位、核心产品价格长期低迷。这家曾经的维生素B2龙头，究竟陷入了怎样的困局？6亿元 资金能否成为解困的"灵丹妙药"。 针对此次定增的具体安排以及公司经营方面的问题，《中国经营报》记者日前向广济药业方面致函采 访，公司证券部工作人员表示，会将 ...

（文章来源：证券日报） 证券日报网讯 2月25日，广济药业在互动平台回答投资者提问时表示，截至2026年2月13日，公司股东 总户数30602户。 ...

Core Viewpoint - On February 23, a total of 34 listed companies had their restricted shares unlocked, with a total market value of approximately 19.007 billion yuan [1] Group 1: Restricted Share Unlocking Details - Luzhou Laojiao (000568) had 2.0425 million shares unlocked under equity incentive restrictions - AVIC Xi'an Aircraft Industry (000768) had 4.3606 million shares unlocked under equity incentive restrictions - Hubei Energy (000883) had 19.2779 million shares unlocked under equity incentive restrictions - Jining Pharmaceutical (000919) had 1.92 million shares unlocked under equity incentive restrictions - Guangji Pharmaceutical (000952) had 2.5209 million shares unlocked under equity incentive restrictions - China Software (600536) had 57,200 shares unlocked under equity incentive restrictions - Xinhua Medical (600587) had 1.7845 million shares unlocked under equity incentive restrictions - Baoxin Software (600845) had 10.2578 million shares unlocked under equity incentive restrictions - China Railway (601390) had 55.9338 million shares unlocked under equity incentive restrictions - China Communications Construction (601800) had 5.593 million shares unlocked under equity incentive restrictions - StarNet Ruijie (002396) had 2.8342 million shares unlocked under equity incentive restrictions - Lopuskin (002333) had 22.3212 million shares unlocked under A-share issuance to legal persons - Wanbangda (300055) had 33.6538 million shares unlocked under A-share issuance to legal persons - Hangyang Co., Ltd. (002430) had 5.2049 million shares unlocked under equity incentive restrictions - Taijia Co., Ltd. (002843) had 949,600 shares unlocked under equity incentive restrictions - Nanda Optoelectronics (300346) had 130,000 shares unlocked under equity incentive restrictions - Anhui Natural Gas (603689) had 2.5064 million shares unlocked under equity incentive restrictions - Zhongyan Dadi (003001) had 97,200 shares unlocked under equity incentive restrictions - Yuanxiang New Materials (301300) had 30.2983 million shares unlocked with extended lock-up period - Yidao Information (001314) had 88.6187 million shares unlocked under pre-issuance restrictions - Tongda Electric (603390) had 579,500 shares unlocked under equity incentive restrictions - Yangzhou Jinqiao (603307) had 50 million shares unlocked under pre-issuance restrictions - Aili Home (603221) had 2.29 million shares unlocked under equity incentive restrictions - Zhili Fang (301312) had 333,900 shares unlocked under equity incentive restrictions - Kuntai Co., Ltd. (001260) had 83.25 million shares unlocked under pre-issuance restrictions - Entropy Technology (301330) had 92.5223 million shares unlocked with extended lock-up period - Yatong Precision (603190) had 596,100 shares unlocked under pre-issuance restrictions - Sanwang Communication (688618) had 87,400 shares unlocked - Longxun Co., Ltd. (688486) had 30.6312 million shares unlocked - Dize Pharmaceutical (688192) had 991,100 shares unlocked - Haohan Depth (688292) had 57.5177 million shares unlocked - Haizheng Biomaterials (688203) had 78.5601 million shares unlocked - Diaomicro (688381) had 55.9536 million shares unlocked - Zhongrun Optics (688307) had 29.8507 million shares unlocked [1]

中国经济网北京2月22日讯 广济药业(000952.SZ)近日发布2026年向特定对象发行A股股票预案。公司本次发行拟 募集资金总额不超过60,000.00万元（含本数），扣除发行费用后用于偿还借款和补充流动资金。 本次向特定对象发行股票的发行对象为长江产业集团，拟以现金方式全额认购公司本次向特定对象发行的股 票。 本次向特定对象发行股票的定价基准日为第十一届董事会第十五次（临时）会议公告日。本次发行的发行价格 为6.32元/股，不低于定价基准日前二十个交易日公司股票交易均价的80%（定价基准日前二十个交易日股票交易均 价=定价基准日前二十个交易日股票交易总额/定价基准日前二十个交易日股票交易总量）。 本次发行股票数量不超过94,936,708股（含本数），不超过本次发行前公司总股本的30%，最终发行数量将在本 次发行通过深交所审核并经中国证监会同意注册后，按照相关规定，由上市公司股东会授权董事会根据中国证监会 相关规定及实际认购情况与保荐机构（主承销商）协商确定。 本次向特定对象发行的股票种类为人民币普通股（A股），每股面值为人民币1.00元。本次发行采取向特定对象 发行的方式。公司将在深交所审核通过并取得 ...

（文章来源：新京报） 新京报讯（记者刘旭）2月11日，湖北广济药业股份有限公司（简称"广济药业"）发布2026年向特定对 象发行A股股票预案，公司拟向控股股东长江产业集团发行股票募资不超过6亿元，扣除发行费用后将 全部用于偿还借款及补充流动资金。本次发行价格为6.32元/股。 广济药业表示，截至2025年9月30日，公司的资产负债率为62.67%，公司目前较高的资产负债率加大了 公司债务融资的成本，本次发行有利于公司优化资本结构，提高抗风险能力。同时，有利于稳固公司股 权结构，提升公司控制权稳定性；也有利于向社会公众传递积极信息，提升公司投资价值。 2025年10月以来，广济药业董事会曾四次审议通过向银行申请综合授信额度的议案，目的均为实现业务 发展和正常经营所需，包括：向中国民生银行股份有限公司武汉分行申请综合授信1.5亿元，授信期限1 年（其中中长期流动资金贷款支用额度不超过1亿元，期限不超过2年），担保方式为抵押，年利率不超 过3%；向华夏银行黄冈分行申请1.25亿元综合授信，其中1亿元可用于短期流动资金贷款，年利率不超 过2.98%，或开具1.25亿元银行承兑汇票，无抵押担保，资金用途包括采购原材料、 ...

Core Viewpoint - Hubei Guangji Pharmaceutical Co., Ltd. plans to issue up to 94,936,708 A-shares to its controlling shareholder, Changjiang Industrial Investment Group, raising a total of no more than 600 million yuan, which will improve the company's financial status and enhance its resilience against macroeconomic fluctuations [1][3] Group 1: Fundraising and Shareholding Structure - The fundraising will be used to repay loans and supplement working capital, which is expected to improve the company's financial condition [3][5] - After the issuance, Changjiang Industrial Group's shareholding will significantly increase, demonstrating the controlling shareholder's confidence in the company's long-term development [1][3] Group 2: Strategic Positioning and Industry Context - Changjiang Industrial Group is the only provincial-level industrial investment platform in Hubei, focusing on strategic emerging industries, including biomedicine [3][4] - The company aligns with Hubei's "14th Five-Year Plan," which emphasizes the development of high-end medical devices and biomedicine as key growth areas [4] Group 3: Business Structure and Competitive Advantages - Guangji Pharmaceutical is a major global supplier of Vitamin B2, with a market share of approximately 30%, and has a strong operational efficiency and cost control [5][7] - The company has a long history of technological accumulation in Vitamin B2 production, maintaining stable customer relationships and a robust supply chain [7][9] Group 4: Market Trends and Future Outlook - The Vitamin B2 market is entering a down cycle but is expected to recover as global feed demand increases and synthetic biology technology reshapes cost structures [9] - The 600 million yuan fundraising is seen as the beginning of a transformation from a traditional manufacturer to a health platform enterprise [9]

本报讯 （记者李万晨曦）2月12日，湖北广济药业股份有限公司（以下简称"广济药业"）公告拟向控股 股东长江产业投资集团有限公司（以下简称"长江产业集团"）定增募资。本次发行股票数量不超过 94936708股，价格为6.32元/股，募集资金总额不超过6亿元。 三是有利于向社会公众传递积极信息，提升本公司投资价值。本次发行的股票由公司控股股东全额认 购，向市场传递出积极信号，彰显控股股东长江产业集团对广济药业未来发展的坚定信心，有助于提振 二级市场投资情绪、树立公司正面形象，并进一步提高其投资价值，进而实现可持续发展、全体股东利 益最大化通过本次向特定对象发行股票，广济药业的财务状况将得到改善，募集资金使用方向为偿还借 款和补充流动资金，有利于加强其应对宏观经济波动的抗风险能力，从而提升公司的核心竞争能力和持 续盈利能力，实现股东利益最大化。 长江产业集团将现金全额认购，所购股份36个月内不得转让。资金主要用于偿还借款和补充流动资金， 以优化资本结构，降低资产负债率。据广济药业公告，此次定增的影响有以下几个方面： （编辑 张昕） 一是有利于广济药业优化资本结构，提高抗风险能力。截至2025年9月30日，该公司的资 ...

Core Viewpoint - Guangji Pharmaceutical (000952) plans to raise up to 600 million yuan through a private placement to its controlling shareholder, Changjiang Industrial Group, at a price of 6.32 yuan per share, aimed at optimizing its capital structure and addressing financial pressures [1] Group 1: Fundraising and Financial Strategy - The funds raised will be used to repay loans and supplement working capital, with the company's debt-to-asset ratio standing at 62.67% as of September 30, 2025 [1] - The controlling shareholder's stake will increase from 25.26% to 41.33%, indicating strong support for the company [1] Group 2: Performance Forecast - The company anticipates a net loss of between 399 million yuan and 518 million yuan for 2025, marking the third consecutive year of losses, following losses of 140 million yuan in 2023 and 295 million yuan in 2024 [1] - Revenue has declined for two consecutive years, with 2024 revenue reported at 639 million yuan, a year-on-year decrease of 13.42% [3] Group 3: Recent Developments - On February 13, 2026, the company announced the receipt of a drug registration certificate for Mecobalamin tablets, which are used for the treatment of peripheral neuropathy [1] - The company also faces potential shareholder compensation risks due to possible information disclosure issues [1] Group 4: Market Performance - Over the past week (February 9 to 13, 2026), Guangji Pharmaceutical's stock price has shown a slight upward trend, with a price increase of 1.64% and a trading range fluctuation of 5.29% [2] - On February 13, the stock closed at 8.07 yuan, up 1.51%, with a trading volume of 94.31 million yuan and a turnover rate of 3.35% [2] - Technical indicators suggest a weak bullish signal, with the stock touching the upper Bollinger Band at 8.33 yuan [2] Group 5: Institutional Insights - Overall institutional ratings are neutral, with no significant bullish or bearish views [4] - The fund holding ratio is only 0.04%, indicating low institutional interest and activity [4] - Market attention remains moderate, with no clear directional guidance from public sentiment regarding short-term events [4]

Policy Developments - The National Health Commission announced the initiation of HPV vaccination for eligible girls starting in late February, aiming to provide free vaccination services to prevent high-risk HPV infections and reduce cervical cancer incidence [2]. Drug and Device Approvals - Fosun Pharma's subsidiary received approval for clinical trials of HLX15-SC, a monoclonal antibody for multiple myeloma treatment, with a cumulative R&D investment of approximately RMB 191.53 million expected by January 2026 [4]. - Hanyu Pharmaceutical received FDA approval for its acetate glatiramer injection, which treats relapsing multiple sclerosis, enhancing its product pipeline in the U.S. market [5]. Capital Markets - Guangji Pharmaceutical plans to raise up to RMB 600 million through a private placement of shares to repay loans and supplement working capital, pending necessary approvals [7]. - Bonasia and Zhejiang Jingxin Pharmaceutical submitted applications for listing on the Hong Kong Stock Exchange, with respective sponsors [8][9]. Clinical Innovations - A successful brain-machine interface surgery was performed in Guangxi, marking a significant advancement in clinical applications of this technology, with the market projected to reach RMB 3.2 billion by 2024, growing at 18.8% [10]. Research Developments - Researchers from the Wuhan Institute of Virology reported that the oral nucleoside prodrug VV261 effectively inhibits Chikungunya virus replication, supporting its potential new indications [11]. - Northwestern University scientists developed an advanced human spinal cord injury organoid model, providing a platform for testing new regenerative therapies [12]. Public Sentiment Alerts - McAudie announced a lawsuit against Shenyang Sixth People's Hospital over a contract dispute involving over RMB 319.82 million, with the case currently accepted by the court [14]. - The National Medical Insurance Administration listed 153 companies as "discredited," which may face restrictions on their products and services based on their credit ratings [15].